9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.

      Nature reviews. Cancer

      Anti-Inflammatory Agents, Non-Steroidal, pharmacology, Antineoplastic Agents, Apoptosis, drug effects, Diet, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Humans, Models, Biological, NF-kappa B, antagonists & inhibitors, genetics, Proteome, Steroids

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The cytotoxicity of chemotherapeutic agents is attributed to apoptosis. Acquired resistance to the effects of chemotherapy has emerged as a significant impediment to effective cancer therapy. One feature that cytotoxic treatments of cancer have in common is their activation of the transcription factor nuclear factor-kappaB (NF-kappaB), which regulates cell survival. NF-kappaB activation suppresses the apoptotic potential of chemotherapeutic agents and contributes to resistance. What evidence is there that inhibitors of NF-kappaB might promote apoptosis in cancer cells and can NF-kappaB inhibitors be used to overcome resistance to chemotherapeutic agents?

          Related collections

          Author and article information

          Journal
          15803156
          10.1038/nrc1588

          Comments

          Comment on this article